311C90, A new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: A double-blind, placebo-controlled, dose-range finding study

Neurology

Volumn 46, Issue 2, 1996, Pages 522-526

  Visser, W H ^a   Klein, K B ^b   Cox, R C ^b   Jones, D ^b   Ferrari, M D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; PLACEBO; SEROTONIN 1 AGONIST; SEROTONIN 1D RECEPTOR; ZOLMITRIPTAN;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLES; OXAZOLIDINONES; PAIN MEASUREMENT; PLACEBOS; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 0029926020     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.2.522     Document Type: Article

References (22)

1. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-311.
2. Humphrey PPA, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991;12:444-445.
3. Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci 1993;14:129-133.
4. Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low availability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol 1983;16:695-699.
5. Tfelt-Hansen P, Johnson ES. Ergotamine. In Olesen J, Tfelt-Hansen P, Welch KMA, eds. The headaches. New York: Raven Press, 1993:313-322.
6. Tfelt-Hansen P, Lipton RB. Dihydroergotamine. In Olesen J, Tfelt-Hansen P, Welch KMA, eds. The headaches. New York: Raven Press, 1993:323-327.
7. The Oral Sumatriptan Dose Finding Study Group. Sumatriptan - a dose-defining study. Eur Neurol 1991;31: 300-305.
8. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994;47:622-651.
9. Ferrari MD, et al and The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-321.
10. Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol 1991;31:323-331.
11. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991;31:291-294.
12. Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrence. Cephalalgia 1994;14:330-338.
13. 1D receptor agonist 311C90. In Rose CF; ed. New advances in headache research. London: Smith-Gordon, 1994:3-4.
14. Martin GR, MacLennan SJ, Cambridge D, Whiting MV. Effect of 311C90 on regional blood flows and systemic haemodynamics in anaesthetised dogs and cats. Headache 1994;34:311.
15. Saxena PR, Tfelt-Hansen P. Sumatriptan. In Olesen J, Tfelt-Hansen P, Welch KMA, eds. The headaches. New York: Raven Press, 1993:329-341.
16. 1D agonist 311C90. Headache 1994;34:299.
17. Schoenen J, Caekebeke J, Louis P, Mouseu G, Philips S, Pierre P. An open study to investigate the absorption and tolerability of oral 311C90 and to obtain a preliminary indication of efficacy in migraine patients. In Rose CF, ed. New advances in headache research. London: Smith-Gordon, 1994: 11-14.
18. Thomsen L, Lassen L, Bendtsen L, Daugaard D, Dixon R, Olesen J. An open, cross-over study to compare the absorption of a 10 mg oral dose of 311C90 during and outside a migraine attack and to obtain a preliminary indication of efficacy in migraine. In Rose CF, ed. New advances in headache research. London: Smith-Gordon 1994:13-14.
19. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988;8(suppl. 7)19-28.
20. Rapoport AM, Visser WH, Cutler NR, et al. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology (in press).
21. The Oral Sumatriptan Multiple-Dose Study Group. Evaluation of a multiple dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991;31:306-313.
22. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-2835.